Lakefront Biotherapeutics - Sponsored ADR

LKFT Healthcare Biotechnology

Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.

Revenue
−95.4%
EPS
+198.9%
Free cash flow
+18.2%

Quarter to June 2026, against a year earlier

33.47 0.09 −0.27%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−15.3×
Dividend yield
—
F-score
6/9
Altman Z
8.43
Beneish M
0.34
Dividend safety
n/a

Lakefront Biotherapeutics - Sponsored ADR (LKFT) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Lakefront Biotherapeutics - Sponsored ADR (LKFT) trades at a EV/FCF of 0.6×. Over the past ten years it has ranged from −37.7× (July 2019) to 42.6× (June 2018); the current reading is higher than 23% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 1.7× (5.73%)
FY2024 1.8× 9.16%
FY2023 1.7× (30.96%)
FY2022 2.4× (15.74%)
FY2021 2.9× —
FY2020 −1.0× —
FY2019 1.5× —
FY2018 −17.7× —
FY2017 25.3× 99.88%
FY2016 12.6× —

Quarterly newest first

Period EV/FCF Change
Mar 2026 2.5× (5.32%)
Mar 2025 2.6× 14.04%
Mar 2024 2.3× 3.33%
Sep 2023 2.2× (15.59%)
28 more quarters

Against its own ten years

Low −37.7× High 42.6×
Ten-year median 2.1×
Current reading's percentile 1

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on LKFT